Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Lisdexamfetamine Dimesylate (LDX) 30 mg	78
Overall Study	STARTED	LDX 50 mg	79
Overall Study	STARTED	LDX 70 mg	78
Overall Study	STARTED	Placebo	79
Overall Study	COMPLETED	Lisdexamfetamine Dimesylate (LDX) 30 mg	63
Overall Study	COMPLETED	LDX 50 mg	66
Overall Study	COMPLETED	LDX 70 mg	67
Overall Study	COMPLETED	Placebo	69
Overall Study	NOT COMPLETED	Lisdexamfetamine Dimesylate (LDX) 30 mg	15
Overall Study	NOT COMPLETED	LDX 50 mg	13
Overall Study	NOT COMPLETED	LDX 70 mg	11
Overall Study	NOT COMPLETED	Placebo	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00735371/flow